Compare Ascendis Pharma A/S (ASND) vs iShares MSCI Japan ETF (EWJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares MSCI Japan ETF — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while iShares MSCI Japan ETF trades at $93.22. Which is the better fit depends on your goals.
| ASND | EWJ | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $96.97 |
52-Week Low | $163.32 | $71.69 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
EWJ, the iShares MSCI Japan ETF, trades at $94.55, up 1.1% today, with a bullish technical signal from moving averages. The fund tracks Japanese equities, facing currency headwinds as the yen weakens against the dollar. Recent news highlights potential FX intervention by Japanese authorities to support the yen, which could impact returns for USD-based investors. Technical indicators show support at $92 and resistance at $95, with neutral oscillators suggesting limited momentum.
The outlook for EWJ is mixed, with opportunities from Japan's domestic investment push and AI-driven stock gains, but risks include yen volatility and economic sensitivity. Investors should weigh currency-hedged options to mitigate FX drag, as structural reforms and pension fund shifts may offer long-term growth amid near-term uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →
